Platelet counts in patients with ITP during initial sutimlimab treatment (part A), washout, and retreatment (part B)
| . | Median (range) platelet count, ×109/L, (N = 12) . |
|---|---|
| Part A | |
| Baseline∗ | 19 (1-57), n = 12 |
| Day 1 | 36 (0-209), n = 12 |
| Day 4 | 29 (3-611), n = 12 |
| Day 7 | 48 (16-435), n = 12 |
| Day 14 | 74 (2-205), n = 10 |
| Day 133 (EOT-A) | 54 (16-319), n = 7 |
| Washout | |
| Day 134 | 66 (20-311), n = 7 |
| Day 154 | 62 (19-270), n = 4 |
| Day 196 | 6 (6-6), n = 1 |
| Part B | |
| Study baseline∗ | 23 (5-57), n = 7 |
| Day 0 (8 h after dose) | 34 (7-54), n = 4 |
| Day 4 | 48 (7-146), n = 7 |
| Day 7 | 43 (7-416), n = 7 |
| Day 441 | 101 (36-355), n = 4 |
| Day 455 (EOT-B) | 146 (31-303), n = 5 |
| . | Median (range) platelet count, ×109/L, (N = 12) . |
|---|---|
| Part A | |
| Baseline∗ | 19 (1-57), n = 12 |
| Day 1 | 36 (0-209), n = 12 |
| Day 4 | 29 (3-611), n = 12 |
| Day 7 | 48 (16-435), n = 12 |
| Day 14 | 74 (2-205), n = 10 |
| Day 133 (EOT-A) | 54 (16-319), n = 7 |
| Washout | |
| Day 134 | 66 (20-311), n = 7 |
| Day 154 | 62 (19-270), n = 4 |
| Day 196 | 6 (6-6), n = 1 |
| Part B | |
| Study baseline∗ | 23 (5-57), n = 7 |
| Day 0 (8 h after dose) | 34 (7-54), n = 4 |
| Day 4 | 48 (7-146), n = 7 |
| Day 7 | 43 (7-416), n = 7 |
| Day 441 | 101 (36-355), n = 4 |
| Day 455 (EOT-B) | 146 (31-303), n = 5 |
EOT-A, part A end of treatment; EOT-B, part B end of treatment; ITP, immune thrombocytopenia.
Baseline is defined as the average of all nonmissing values before the first dose of sutimlimab in part A and part B, respectively.